Zobrazeno 1 - 10
of 102
pro vyhledávání: '"Carol C. Cheung"'
Autor:
Tracy Tucker, Margaret M. Kelly, Jean-Claude Cutz, Ming-Sound Tsao, Ranjit Waghray, Weei-Yuan Huang, Doha Itani, Christian Couture, Adam C. Smith, Carol C. Cheung, Fariboz Rashid-Kolvear, Emina Torlakovic, Yasushi Yatabe, Anna Bojarski, Michel R. Nasr, Aly Karsan, Zhaolin Xu, Gefei Qing, Iyare Izevbaye, Roula Albadine, Gilbert Bigras, Harmanjatinder S. Sekhon, Joan H.M. Knoll, Alan Spatz, H. Wang, Keith Kwan, Diana N. Ionescu, Tracy Stockley, Danh Tran-Thanh
Publikováno v:
Lung Cancer. 160:127-135
Patients with non-small cell lung cancer (NSCLC) harboring ROS proto-oncogene 1 (ROS1) gene rearrangements show dramatic response to the tyrosine kinase inhibitor (TKI) crizotinib. Current best practice guidelines recommend that all advanced stage no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbff065fcf05b695be82821e9ad32c24
https://doi.org/10.1016/j.lungcan.2021.08.003
https://doi.org/10.1016/j.lungcan.2021.08.003
Autor:
Carol C Cheung, Shehnaz Khan
Publikováno v:
Journal of Clinical Pathology. 72:237-243
The ability to effectively monitor key indicators is important for continuous quality improvement in laboratory immunohistochemistry. This article deals specifically with laboratory turnaround time (TAT) as a key delivery indicator and the impact of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::217dd06215266b0e4cb42bbaa96a7b31
https://doi.org/10.1136/jclinpath-2019-205725
https://doi.org/10.1136/jclinpath-2019-205725
Autor:
Shubhayan Sanatani, Carol C Cheung, Christian Steinberg, Danna A. Spears, Michael H. Gollob, Greg Mellor, Zachary Laksman, Andrew D. Krahn, Robert J. Hamilton, Jeff S. Healey
Publikováno v:
Netherlands Heart Journal
Introduction Phospholamban cardiomyopathy is an inherited cardiomyopathy, characterised by a defect in regulation of the sarcoplasmic reticulum Ca2+ pump, often presenting with malignant arrhythmias and progressive cardiac dysfunction occurring at a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7484efe22cd5a4ac46f329d79e434f0d
http://europepmc.org/articles/PMC6439019
http://europepmc.org/articles/PMC6439019
Autor:
Yuki Leung, Emina Torlakovic, Carol C. Cheung, S. Lau, Michael Cabanero, Jeffrey Tanguay, Prodipto Pal, Rex C. Santiago, Zanobia Khan, Ming-Sound Tsao, Adrian G. Sacher, Tahani Albaqer, Jessica Weiss, David M. Hwang
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 16(9)
Programmed death-ligand 1 (PD-L1) is used as a biomarker for anti-programmed cell death protein-1 (PD-1) or anti-PD-L1 immunotherapies in NSCLC. We report here the results of population-based PD-L1 testing using the 22C3 IHC pharmDx Assay (Agilent Te
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55f347c9fb154bb77fb9e49e1e1b2db7
https://pubmed.ncbi.nlm.nih.gov/33915250
https://pubmed.ncbi.nlm.nih.gov/33915250
Autor:
Zhaolin Xu, Kenneth J. Craddock, Diana N. Ionescu, Prashant Dhamanaskar, Alexander Boag, Roula Albadine, Emina Torlakovic, Sophie Camilleri-Broët, Gefei Qing, H. Wang, Carol C. Cheung, Hyun J. Lim, Alan Spatz, Søren Nielsen, Ming-Sound Tsao, Pierre Fiset, Harman Sekhon, Anna Bojarski, David M. Hwang, Jean-Claude Cutz, Margaret M. Kelly, Ranjit Waghray, Gilbert Bigras, Keith Kwan, Christian Couture, Michael Cabanero, Mohammad Hossain, Doha Itani
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 15(8)
Introduction The programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) assay is used to select patients for first or second-line pembrolizumab monotherapy in NSCLC. The PD-L1 IHC 22C3 pharmDx assay requires an Autostainer Link 48 instrument. L
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb22831012ba58d2da49dd2c1bd22c6c
https://pubmed.ncbi.nlm.nih.gov/32304736
https://pubmed.ncbi.nlm.nih.gov/32304736
Autor:
Gilad W. Vainer, H. Wang, Julien Adam, Catherine L. Ross, Ka F. To, Gilbert Bigras, Diana N. Ionescu, Ming-Sound Tsao, Paul E. Swanson, Chao Li, Anthony W.H. Chan, Jin Haeng Chung, Zhaolin Xu, Katsuhiro Okuda, Marianne Ratcliffe, Rasmus Røge, Maria S. Tretiakova, Andreas H. Scheel, Marius Ilie, Hyun J. Lim, Gang Han, Daichi Fujimoto, Enrico Munari, Dirk Zielinski, Emina Torlakovic, Fred R. Hirsch, Penny J. Barnes, David L. Rimm, Ross A. Soo, Pierre Fiset, Christian Couture, Carol C Cheung
Publikováno v:
Torlakovic, E, Lim, H J, Adam, J, Barnes, P, Bigras, G, Chan, A W H, Cheung, C C, Chung, J-H, Couture, C, Fiset, P O, Fujimoto, D, Han, G, Hirsch, F R, Ilie, M, Ionescu, D, Li, C, Munari, E, Okuda, K, Ratcliffe, M J, Rimm, D L, Ross, C, Røge, R, Scheel, A H, Soo, R A, Swanson, P E, Tretiakova, M, To, K F, Vainer, G W, Wang, H, Xu, Z, Zielinski, D & Tsao, M-S 2020, ' "Interchangeability" of PD-L1 immunohistochemistry assays : a meta-analysis of diagnostic accuracy ', Modern Pathology, vol. 33, no. 1, pp. 4-17 . https://doi.org/10.1038/s41379-019-0327-4
Modern Pathology
Modern Pathology
Different clones, protocol conditions, instruments, and scoring/readout methods may pose challenges in introducing different PD-L1 assays for immunotherapy. The diagnostic accuracy of using different PD-L1 assays interchangeably for various purposes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad64999e64af73e6d8c2a5bc82d73cdf
https://vbn.aau.dk/ws/files/320397307/Torlakovic_et_al_2020_Interchangeability_of_PD_L1_immunohistochemistry_assays.pdf
https://vbn.aau.dk/ws/files/320397307/Torlakovic_et_al_2020_Interchangeability_of_PD_L1_immunohistochemistry_assays.pdf
Publikováno v:
Applied Immunohistochemistry & Molecular Morphology. 25:308-312
Appropriate controls are critical for the correct interpretation of immunohistochemistry (IHC) assays and help to detect unsuccessful/suboptimal slides. We performed an audit of slides that were designated as being "failed" by the IHC laboratory (ie,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa26224d36721988fca756d1aa8aa5e2
https://doi.org/10.1097/pai.0000000000000305
https://doi.org/10.1097/pai.0000000000000305
Autor:
Jagdish Butany, Fiorella Calabrese, Zhaolin Xu, Hyun J. Lim, Pierre Fiset, Adnan Mansoor, Victor A Tron, Emina Torlakovic, Scott L. Boerner, Christian Couture, Hala El-Zimaity, Penny J. Barnes, Gabor Fischer, John Garratt, Sinchita Roy-Chowdhuri, C. Blake Gilks, Lisa Manning, Laurette Geldenhuys, Carol C Cheung, Gilbert Bigras, H. Wang, Catherine Ross, Marius Ilie, Jean Deschenes, Alan Spatz, Robert H. Riddell, Ming-Sound Tsao, Paul E. Swanson, Diana N. Ionescu
Publikováno v:
Applied Immunohistochemistry & Molecular Morphology
Supplemental Digital Content is available in the text.
Since 2014, programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) checkpoint inhibitors have been approved by various regulatory agencies for the treatment of multipl
Since 2014, programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) checkpoint inhibitors have been approved by various regulatory agencies for the treatment of multipl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f3ee6a8d99853b79b889b03a84bac02
https://pubmed.ncbi.nlm.nih.gov/32282341
https://pubmed.ncbi.nlm.nih.gov/32282341
Autor:
Gilda da Cunha Santos, Natasha B. Leighl, Emina Torlakovic, Adam C. Smith, Ming-Sound Tsao, Kelvin Young, Jeffrey Tanguay, Catherine Labbé, Melania Pintilie, Pierre Fiset, Ri Wang, Kenneth J. Craddock, David M. Hwang, Scott L. Boerner, Carol C Cheung, Hyang Mi Ko
Publikováno v:
CancerReferences. 125(22)
Background The presence of anaplastic lymphoma kinase (ALK) rearrangement predicts response to ALK tyrosine kinase inhibitor (TKI) therapy. Fluorescence in situ hybridization (FISH) was the initial reference standard to detect ALK rearrangement, but
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3470246cdf4919069cd0b060edda7938
https://pubmed.ncbi.nlm.nih.gov/31390053
https://pubmed.ncbi.nlm.nih.gov/31390053
Publikováno v:
Applied immunohistochemistrymolecular morphology : AIMM. 27(4)
PD-L1 testing by immunohistochemistry (IHC) has presented significant challenges not only for clinical laboratories, but also for external quality assurance (EQA) entities that provide proficiency testing (PT) for clinical laboratories. Canadian Immu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9324146a3c64459ae631c803e28f9d9
https://pubmed.ncbi.nlm.nih.gov/30720467
https://pubmed.ncbi.nlm.nih.gov/30720467